Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016;51(4):1069-83.
doi: 10.3233/JAD-150731.

Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies

Olivier Bousiges  1   2 , Benjamin Cretin  3   4   5 , Thomas Lavaux  1 , Nathalie Philippi  3   4   5   6 , Barbara Jung  3   4   5   6 , Sylvie Hezard  1 , Camille Heitz  3   4   5 , Catherine Demuynck  3   4   5   6 , Aurelia Gabel  1 , Catherine Martin-Hunyadi  5   6 , Frédéric Blanc  3   4   5   6
Affiliations

Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies

Olivier Bousiges et al. J Alzheimers Dis. 2016.

Abstract

Background: Dementia with Lewy bodies (DLB) symptoms are close to those of Alzheimer's disease (AD), and the differential diagnosis is difficult especially early in the disease. Unfortunately, AD biomarkers in cerebrospinal fluid (CSF), and more particularly Aβ1 - 42, appear to be altered in dementia with Lewy bodies (DLB). However, the level of these biomarkers has never been studied in the prodromal stage of the disease.

Objective: To compare these biomarkers between DLB and AD, with a particular focus on the prodromal stage.

Methods: A total of 166 CSF samples were collected at the memory clinic of Strasbourg. They were obtained from prodromal DLB (pro-DLB), DLB dementia, prodromal AD (pro-AD), and AD dementia patients, and elderly controls. Phospho-Tau181, total-Tau, Aβ42, and Aβ40 were measured in the CSF.

Results: At the prodromal stage, contrary to AD patients, DLB patients' biomarker levels in the CSF were not altered. At the demented stage of DLB, Aβ42 levels were reduced as well as Aβ40 levels. Thus, the Aβ42/Aβ40 ratio remained unchanged between the prodromal and demented stages, contrary to what was observed in AD. Tau and Phospho-Tau181 levels were unaltered in DLB patients.

Conclusions: We have shown that at the prodromal stage the DLB patients had no pathological profile. Consequently, CSF AD biomarkers are extremely useful for differentiating AD from DLB patients particularly at this stage when the clinical diagnosis is difficult. Thus, these results open up new perspectives on the interpretation of AD biomarkers in DLB.

Keywords: Alzheimer’s disease; Aβ40; Aβ42; Aβ42/Aβ40 ratio; cerebrospinal fluid biomarkers; dementia; dementia with Lewy bodies; phospho-Tau181; prodromal; total-Tau.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • The Use of Antimicrobial and Antiviral Drugs in Alzheimer's Disease.
    Iqbal UH, Zeng E, Pasinetti GM. Iqbal UH, et al. Int J Mol Sci. 2020 Jul 12;21(14):4920. doi: 10.3390/ijms21144920. Int J Mol Sci. 2020. PMID: 32664669 Free PMC article. Review.
  • White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation.
    Teunissen CE, Otto M, Engelborghs S, Herukka SK, Lehmann S, Lewczuk P, Lleó A, Perret-Liaudet A, Tumani H, Turner MR, Verbeek MM, Wiltfang J, Zetterberg H, Parnetti L, Blennow K. Teunissen CE, et al. Alzheimers Res Ther. 2018 Mar 15;10(1):30. doi: 10.1186/s13195-018-0359-x. Alzheimers Res Ther. 2018. PMID: 29544527 Free PMC article. Review.
  • β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies.
    Ferreira D, Przybelski SA, Lesnick TG, Lemstra AW, Londos E, Blanc F, Nedelska Z, Schwarz CG, Graff-Radford J, Senjem ML, Fields JA, Knopman DS, Savica R, Ferman TJ, Graff-Radford NR, Lowe VJ, Jack CR Jr, Petersen RC, Mollenhauer B, Garcia-Ptacek S, Abdelnour C, Hort J, Bonanni L, Oppedal K, Kramberger MG, Boeve BF, Aarsland D, Westman E, Kantarci K. Ferreira D, et al. Neurology. 2020 Dec 15;95(24):e3257-e3268. doi: 10.1212/WNL.0000000000010943. Epub 2020 Sep 28. Neurology. 2020. PMID: 32989106 Free PMC article.
  • Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies.
    Foska A, Tsantzali I, Sideri E, Stefanou MI, Bakola E, Kitsos DK, Zompola C, Bonakis A, Giannopoulos S, Voumvourakis KI, Tsivgoulis G, Paraskevas GP. Foska A, et al. Medicina (Kaunas). 2022 Apr 28;58(5):612. doi: 10.3390/medicina58050612. Medicina (Kaunas). 2022. PMID: 35630029 Free PMC article.
  • Faster decline of very prodromal dementia with Lewy bodies when amyloid positive.
    Blanc F, Bouteloup V, Paquet C, Chupin M, Pasquier F, Gabelle A, Ceccaldi M, de Sousa PL, Krolak-Salmon P, David R, Fischer C, Dartigues JF, Wallon D, Moreaud O, Sauvée M, Belin C, Roubaud Baudron C, Botzung A, Ravier A, Demuynck C, Namer I, Habert MO, Bousiges O, Schorr B, Muller C, Philippi N, Chêne G, Cretin B, Mangin JF, Dufouil C. Blanc F, et al. Alzheimers Dement (Amst). 2025 Jun 24;17(2):e70141. doi: 10.1002/dad2.70141. eCollection 2025 Apr-Jun. Alzheimers Dement (Amst). 2025. PMID: 40568304 Free PMC article.
See all "Cited by" articles

Publication types